

## Washington University School of Medicine Digital Commons@Becker

---

### Open Access Publications

---

2017

# Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in *Acinetobacter* species

Rachel L. Kinsella

*Washington University School of Medicine in St. Louis*

Juvenal Lopez

*Washington University School of Medicine in St. Louis*

Lauren D. Palmer

*Vanderbilt University*

Nichole D. Salinas

*Washington University School of Medicine in St. Louis*

Eric P. Skaar

*Vanderbilt University*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open\\_access\\_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

---

### Recommended Citation

Kinsella, Rachel L.; Lopez, Juvenal; Palmer, Lauren D.; Salinas, Nichole D.; Skaar, Eric P.; Tolia, Niraj H.; and Feldman, Mario F., "Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in *Acinetobacter* species." *Journal of Biological Chemistry*.292,48. 19628-19638. (2017).  
[https://digitalcommons.wustl.edu/open\\_access\\_pubs/6376](https://digitalcommons.wustl.edu/open_access_pubs/6376)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [engeszer@wustl.edu](mailto:engeszer@wustl.edu).

---

**Authors**

Rachel L. Kinsella, Juvenal Lopez, Lauren D. Palmer, Nichole D. Salinas, Eric P. Skaar, Niraj H. Tolia, and Mario F. Feldman



# Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in *Acinetobacter* species

Received for publication, July 25, 2017, and in revised form, October 2, 2017. Published, Papers in Press, October 5, 2017, DOI 10.1074/jbc.M117.808394

Rachel L. Kinsella<sup>‡S1</sup>, Juvenal Lopez<sup>‡2</sup>, Lauren D. Palmer<sup>‡13</sup>, Nichole D. Salinas<sup>‡</sup>, Eric P. Skaar<sup>14</sup>, Niraj H. Tolia<sup>‡</sup>, and Mario F. Feldman<sup>‡5</sup>

From the <sup>‡</sup>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, the <sup>S</sup>Department of Biological Sciences, University of Alberta, Edmonton T6G 2E9, Alberta, Canada, and the <sup>1</sup>Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232

Edited by Chris Whitfield

*Acinetobacter baumannii*, *Acinetobacter nosocomialis*, and *Acinetobacter pittii* are a frequent cause of multidrug-resistant, healthcare-associated infections. Our previous work demonstrated that *A. nosocomialis* M2 possesses a functional type II secretion system (T2SS) that is required for full virulence. Further, we identified the metallo-endopeptidase CpaA, which has been shown previously to cleave human Factor V and deregulate blood coagulation, as the most abundant type II secreted effector protein. We also demonstrated that its secretion is dependent on CpaB, a membrane-bound chaperone. In this study, we show that CpaA expression and secretion are conserved across several medically relevant *Acinetobacter* species. Additionally, we demonstrate that deletion of *cpaA* results in attenuation of *A. nosocomialis* M2 virulence in moth and mouse models. The virulence defects resulting from the deletion of *cpaA* were comparable with those observed upon abrogation of T2SS activity. The virulence defects resulting from the deletion of *cpaA* are comparable with those observed upon abrogation of T2SS activity. We also show that CpaA and CpaB strongly interact, forming a complex in a 1:1 ratio. Interestingly, deletion of the N-terminal transmembrane domain of CpaB results in robust secretion of CpaA and CpaB, indicating that the transmembrane domain is dispensable for CpaA secretion and likely functions to retain CpaB inside the cell. Limited proteolysis of spheroplasts revealed that the C-terminal domain of CpaB is exposed to the periplasm, suggesting that this is the site where CpaA and CpaB interact *in vivo*. Last, we show that CpaB does not abolish the

proteolytic activity of CpaA against human Factor V. We conclude that CpaA is, to the best of our knowledge, the first characterized, *bona fide* virulence factor secreted by *Acinetobacter* species.

Bacterial protein secretion is one way in which cells interact with and impact their environment. For instance, toxins and hydrolytic enzymes secreted by the type II secretion system (T2SS)<sup>6</sup> aid in nutrient acquisition and promote *in vivo* survival and virulence of several pathogens, including *Vibrio cholerae*, enterotoxigenic *Escherichia coli*, *Pseudomonas aeruginosa*, and *Legionella pneumophila* (1–7). The T2SS is composed of an outer membrane secretin, a periplasmic pseudopilus, an inner membrane platform, and a cytoplasmic ATPase, and it is widespread among pathogenic and non-pathogenic Gram-negative bacteria (8–11). Secretion through the T2SS is a two-step process. First, type II substrates are translocated from the cytosol to the periplasmic space by either the general secretory (Sec) pathway or the Twin-arginine translocation (Tat) system (10, 11). Then, folded type II substrates are pushed through the outer membrane secretin and into the extracellular space via pseudopilus polymerization. Although type II substrates associate with the secretion apparatus through interactions with the outer membrane secretin, components of the inner membrane platform, and/or components of the pseudopilus, including the major pseudopilin and the minor pseudopilins (12–14), it is not well-understood how type II substrates are targeted to the type II secretion apparatus and differentially recognized relative to other fully folded soluble periplasmic proteins (12).

*Acinetobacter baumannii* is among the most threatening multidrug-resistant nosocomial pathogens worldwide. In fact, the World Health Organization has recently categorized it as a critical priority for the research and development of new antibiotics (15). However, it is important to highlight that the entire *Acinetobacter calcoaceticus*–*A. baumannii* complex, which is comprised primarily of *A. baumannii*, *Acinetobacter nosocomialis*, *A. calcoaceticus*, and *Acinetobacter pittii*, is becoming

This work was supported by a startup fund to M. F. F. from the Department of Molecular Microbiology at Washington University School of Medicine. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains supplemental Figs. S1–S5 and Tables S1 and S2.

<sup>1</sup> Supported by Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarships-Doctoral Program (NSERC PGSD) and Washington University Schlessinger awards.

<sup>2</sup> Supported by a Washington University Chancellor's graduate fellowship.

<sup>3</sup> Funded by National Institutes of Health Grants F32AI122516 and T32HL094296.

<sup>4</sup> Funded by National Institutes of Health Grant R01 AI101171.

<sup>5</sup> To whom correspondence should be addressed: Dept. of Molecular Microbiology, Washington University School of Medicine, Campus Box 8230, St. Louis, MO 63110. Tel.: 314-747-4473; Fax: 314-362-1232; E-mail: mariofeldman@wustl.edu.

<sup>6</sup> The abbreviations used are: T2SS, type II secretion system; spp., species; T3SS, type III secretion system; nickel-NTA, nickel-nitrilotriacetic acid; AB, *Acinetobacter baumannii*; AY, *Acinetobacter baylyi*; AC, *Acinetobacter calcoaceticus*; AP, *Acinetobacter pittii*; AN, *Acinetobacter nosocomialis*.

an increasing medical concern (16, 17). In addition to being extensively drug-resistant, *Acinetobacter* species (spp.) are capable of forming biofilms and withstanding desiccation as well as a wide range of temperatures and pH values (18–22). Altogether, these features allow *Acinetobacter* to persist in healthcare facilities, where it is a frequent cause of infections such as ventilator-associated pneumonia and bacteremia (23–25).

The presence of T2SS components in *A. baumannii* was first reported in 2014 (26). Subsequently, Johnson *et al.* (27) showed that the T2SS of *A. baumannii* ATCC 17978, a commonly used laboratory strain, is active. Type II–dependent secretion of LipA is required for growth in minimal medium supplemented with long-chain fatty acids as the sole carbon source, indicating an important role in nutrient acquisition (27). Furthermore, the T2SS and T2SS-dependent lipid utilization are required for competitive colonization of a neutropenic murine model of infection (27).

Recently, through heterologous expression and secretion of *A. nosocomialis* M2 (formerly *A. baumannii* M2) T2SS substrates, we demonstrated that *A. baumannii* 19606, *A. nosocomialis* M2, *A. pittii*, *A. calcoaceticus*, and *Acinetobacter junii* also possess a functional T2SS (28). Proteomic comparison of supernatants from wild-type *A. nosocomialis* M2 and an outer membrane secretin *gspD* mutant revealed numerous putative substrate proteins, all with predicted N-terminal Sec signals (28). Three of these substrates, the protease CpaA and the lipases LipA and LipH, were confirmed as T2SS substrates. CpaA was shown previously to be a secreted zinc-dependent metallo-endopeptidase that is capable of degrading fibrinogen and Factor V, thus deregulating blood coagulation (29). Importantly, the T2SS of *A. nosocomialis* is required for full virulence in *Galleria mellonella* and pulmonary murine models of infection (28). Although the wild-type and complemented strains efficiently disseminate to the liver or spleen after intranasal infection, the T2SS-deficient strain does not disseminate as efficiently, suggesting that the T2SS of *A. nosocomialis* plays an important role in virulence. However, the contribution of specific T2SS substrates in virulence has not been investigated.

Similarly to the *P. aeruginosa* type II metallo-protease elastase (34), two *Acinetobacter* T2SS substrates, LipA and CpaA, were found to require chaperones, LipB and CpaB respectively, for their secretion (28). However, unlike elastase, which is produced as a preproelastase, where the prodomain functions as an intramolecular chaperone (30, 31), LipB and CpaB are encoded adjacently to their cognate effector proteins and are predicted to be membrane-bound. CpaB and LipB have no sequence or predicted structural domain similarities (28). Topological prediction servers and bioinformatic analysis of LipB and CpaB suggest that their N-terminal transmembrane domains are imbedded in the inner membrane, with the C-terminal globular portions present in the periplasm (28). CpaB and LipB appear to be specific for CpaA and LipA, respectively, and none of these chaperones are required for the secretion of LipH (28). LipB is functionally similar to the *Burkholderia glumae* type II secretion membrane-bound chaperone lipase-specific foldase (Lif), which is required for the production of enzymatically active lipase. The function of the transmembrane domain of Lif is

unclear, as this domain was not required for the steric chaperone activity of Lif (32–34). It has been proposed that CpaB, LipB, and Lif belong to a novel class of chaperones collectively known as T2SS chaperones (28). The involvement of chaperones in type II secretion is reminiscent of type III secretion systems (T3SSs), where the chaperones are soluble cytoplasmic proteins that interact with a specific substrate or multiple substrates and aid in folding, stabilization, and/or regulation of the secretion of these substrates (35). However, unlike T3SS chaperones, T2SS chaperones do not present any sequence homology and are variable in size and isoelectric point. To our knowledge, CpaB is the first reported membrane-bound, periplasmic chaperone required for secretion of a type II protease.

In this study, employing a combination of mutational and biochemical methods, we investigated the role of CpaA in *A. nosocomialis* pathogenesis and characterized the interaction between CpaA and its T2SS chaperone CpaB. We demonstrate that CpaA is required for virulence against *G. mellonella* larvae and is required for dissemination of *A. nosocomialis* to the spleen in a murine pulmonary model of infection. Furthermore, we show that CpaA and CpaB strongly interact and that the C-terminal periplasmic domain of CpaB is sufficient for chaperone function and interaction with CpaA. Last, we demonstrate that CpaB binding is incapable of blocking the proteolytic activity of CpaA against human Factor V.

## Results


### CpaA is secreted by medically relevant *Acinetobacter* species

The metallopeptidase CpaA is the most abundantly secreted type II substrate in *A. nosocomialis* strain M2 (28). Although older isolates such as *A. baumannii* ATCC 17978 and ATCC 19606 do not encode *cpaA*, the *cpaA* gene is conserved across clinical isolates of *A. baumannii* (29). However, it is unknown whether CpaA is secreted by these strains. To determine the prevalence of CpaA secretion among recent clinical isolates of medically relevant *Acinetobacter* strains, we generated a specific polyclonal antibody against CpaA (see “Experimental procedures” and supplemental Fig. S1). The anti-CpaA antibody was employed to screen various *A. baumannii*, *A. nosocomialis*, and *A. pittii* strains for CpaA expression and secretion. CpaA is present in the supernatant of most of these recent isolates but not in the supernatant of older laboratory strains (Fig. 1). Furthermore, all strains that expressed CpaA secreted the protein. Interestingly, there seems to be strain-to-strain differences in the secretion efficiency of CpaA, suggesting possible differences in the regulation of CpaA secretion. The prevalence of this metallo-peptidase among medically relevant clinical isolates prompted us to investigate the contribution of CpaA to *Acinetobacter* pathogenesis.

### CpaA is required for optimal virulence in *G. mellonella* larvae

We showed previously that the T2SS of *A. nosocomialis* M2 is required for virulence in *G. mellonella* larvae (28). However, we did not identify the specific substrate(s) responsible for this phenotype. Because CpaA is the most abundant T2SS substrate under laboratory conditions, and because it is secreted by many recently isolated strains, we tested the contribution of CpaA to virulence in *G. mellonella*. First, we generated a strain contain-

## Interaction between *CpaA* and chaperone *CpaB*




**Figure 1. CpaA secretion is conserved among medically relevant *Acinetobacter* species.** Whole cells (W) and supernatants (S) of *A. baumannii* (AB), *Acinetobacter baylyi* (AY), *A. calcoaceticus* (AC), *A. pittii* (AP), and *A. nosocomialis* (AN) strains were analyzed by Western blotting using anti-CpaA (green) and anti-RNA polymerase (red) antibodies. CpaA is detected in the supernatants of various AB, AP, and AN strains, all of which are recent clinical isolates. RNA polymerase was included as a lysis control.

ing an unmarked deletion in *cpaA* ( $\Delta$ *cpaA*) and its corresponding complemented strain by inserting a copy of the *cpaAB* locus under its native promoter into the chromosome (*cpaA*+) downstream of *glmS2* (36, 37). We analyzed the supernatant fractions of wild-type *A. nosocomialis* M2,  $\Delta$ *cpaA*, and *cpaA*+ by Western blot analysis. As expected, the strain devoid of *cpaA* did not secrete CpaA. However, CpaA secretion was restored upon complementation by inserting *cpaAB* in the chromosome of M2  $\Delta$ *cpaA* (supplemental Fig. S1). Deletion of *cpaA* and *cpaB* does not alter secretion of the type II substrate LipH, suggesting that CpaB is specific for CpaA and does not broadly impact type II secretion (supplemental Fig. S2).

*G. mellonella* larvae were infected with wild-type M2,  $\Delta$ *cpaA*, or *cpaA*+ (see “Experimental procedures”), and survival was monitored over time (Fig. 2). The  $\Delta$ *gspD* strain carries a deletion in the *gspD* gene that inactivates T2SS and therefore does not secrete any T2SS substrates (28).  $\Delta$ *gspD* and its corresponding complemented strain (*gspD*+) were included for comparison purposes. Twenty-four hours post-infection, 50% of larvae infected with either  $\Delta$ *gspD* or  $\Delta$ *cpaA* survived, whereas infection with wild-type M2, *gspD*+, or *cpaA*+ resulted in less than 25% survival (Fig. 2). The difference in percent survival of larvae infected with either  $\Delta$ *gspD* or  $\Delta$ *cpaA* relative to the wild type or the complemented strains is statistically significant (Fig. 2). Therefore, deletion of *cpaA* results in a virulence defect in *G. mellonella* larvae comparable with the T2SS mutation, suggesting that CpaA is the most important T2SS substrate contributing to the virulence of *A. nosocomialis* M2.

### *CpaA* aids in *A. nosocomialis* dissemination to the spleen in mice

To further confirm the role of CpaA in a mammalian model of infection, we infected mice intranasally with either wild-type,  $\Delta$ *cpaA*, or the *cpaA*+ complemented strain. Thirty-six hours post-infection, the lungs and spleen were harvested and ana-




**Figure 2. Type II secretion and CpaA are similarly required for full virulence in the *G. mellonella* infection model.** *G. mellonella* larvae were injected with 10  $\mu$ l of either M2,  $\Delta$ *gspD*,  $\Delta$ *cpaA*, or the complemented strains at an inoculum of  $\sim 1 \times 10^7$ . Infected larvae were incubated at 37 °C and monitored for viability over time. Viability was determined by melanin accumulation and mobility. Larvae infected with  $\Delta$ *gspD* or  $\Delta$ *cpaA* had  $\sim 50\%$  survival at 24 h. 25% of the larvae infected with M2 survived after 24 h. Larvae infected with the  $\Delta$ *gspD* or  $\Delta$ *cpaA* complemented strains had 17% survival at 24 h post-infection. The difference in percent survival of larvae infected with  $\Delta$ *gspD* or  $\Delta$ *cpaA* relative to the wild-type or complemented strains is statistically significant (Mantel Cox  $p = 0.0447$ ).

lyzed for colony-forming units. Although no significant difference was observed, comparison of the bacterial burden in the lungs of infected mice shows a trend toward decreased colonization by the  $\Delta$ *cpaA* strain relative to the wild-type and complemented strains (Fig. 3A). In contrast, a statistically significant difference was observed in the bacterial burden in the spleens of mice infected with  $\Delta$ *cpaA* compared with mice infected with the complemented strain (Fig. 3B). Furthermore, we confirmed that deletion of both CpaA and CpaB did not affect secretion of other T2SS substrates such as LipH (supplemental Fig. S2). Thus, CpaA appears to play a role in dissemination from the initial site of infection in the lungs to a distal site in the spleen.

### *CpaA* physically interacts with its dedicated chaperone *CpaB*


We showed previously that CpaA secretion is dependent on an uncharacterized protein encoded immediately downstream



**Figure 3. CpaA aids in colonization of the spleen in mice.** Mice were intranasally inoculated with  $1 \times 10^9$  cfus of either wild-type,  $\Delta cpaA$ , or the  $cpaA$  complemented strain. 36 h post-infection, mice were sacrificed, organs were harvested, and colony-forming units were enumerated from homogenized tissue. *A*, total colony-forming units from the lung demonstrate a non-statistically significant trend toward decreased colonization by the  $\Delta cpaA$  strain (Kruskal-Wallis non-parametric,  $p = 0.06$ ). *B*, total colony-forming units from the spleen demonstrate a statistically significant difference between the complemented  $cpaA$  strain and the  $\Delta cpaA$  mutant strain (Kruskal-Wallis non-parametric,  $*p = 0.0327$ ).

of CpaA (28). We designated this protein CpaB because of its proximity to *cpaA*. Domain-enhanced lookup time accelerated (DELTA) BLASTp analysis identified a SRPBCC superfamily domain in CpaB (28). Because proteins with a SRPBCC domain are predicted to have a deep hydrophobic ligand-binding pocket and chaperone-like activity, we postulated that CpaB belongs to a new family of membrane-bound chaperones (T2SS chaperones) that mediate the secretion of specific T2SS substrates (28). T2SS chaperones could facilitate folding, inhibit self-damaging activities by functioning as immunity proteins, and/or pilot the secretion of their cognate substrates. All of these activities require the interaction of the chaperone with its substrate. The physical interaction between CpaB and CpaA was addressed through a pulldown assay. *cpaA* containing a C-terminal FLAG tag and *cpaB* containing a C-terminal hexahistidine tag were both cloned into vector pWH1266 (pWH-*cpaA-flag-cpaB-his*) and expressed in M2  $\Delta cpaAB$ , which lacks the endogenous *cpaA* and *cpaB* genes. Nickel-NTA affinity chromatography was performed on cell lysate solubilized with 0.01% Triton X-100. CpaA-FLAG and CpaB-His were detected by Western blot analysis in the load fraction, indicating that both proteins were expressed (Fig. 4A, left). Despite not detecting CpaA-FLAG in the wash fractions, CpaA-FLAG was detected upon elution of immobilized CpaB-His (Fig. 4A). Moreover, nickel-NTA affinity chromatography on cell lysate from M2  $\Delta cpaAB$ -expressing *cpaA-flag* and untagged *cpaB* (pWH-*cpaA-flag-cpaB*) revealed that CpaA-FLAG is not eluted in the absence of hexahistidine-tagged CpaB (Fig. 4B), indicating that CpaA binds specifically to CpaB. Further, Coomassie staining of the elution from M2  $\Delta cpaAB$  pWH-*cpaA-flag-cpaB-his* lysate suggests that CpaA and CpaB associate specifically in an approximate 1:1 ratio (Fig. 4A, right).

We evaluated the stoichiometry of the CpaA–CpaB complex by size-exclusion chromatography and sedimentation equilibrium analytical centrifugation (Fig. 5). Size-exclusion chromatography of the co-purified complex of CpaA and a transmembrane-truncated CpaB resulted in an aggregate peak starting at a void volume of 40 ml and a complex peak at a volume of 85 ml (Fig. 5A). An SDS-PAGE gel of the complex peak showed two



**Figure 4. CpaA and CpaB strongly interact physically.** *A* and *B*, Western blot analysis of nickel affinity purifications from cell lysates of M2  $\Delta cpaAB$  expressing either pWH-*cpaA-flag-cpaB-his* (*A*) or pWH-*cpaA-flag-cpaB* (*B*). Note that, in *B*, CpaB does not contain a C-terminal hexahistidine tag. CpaA-FLAG was detected using an anti-FLAG monoclonal antibody, whereas CpaB was detected using anti-histidine polyclonal antibodies. The right panel in *A* shows Coomassie-stained SDS-PAGE of the elution from *A* and thus represents the CpaA-FLAG-CpaB-His complex. *L*, loaded cell lysate, *FT*, flow-through, *W1–3*, washes one to three; *E*, elution.


bands corresponding to CpaA and CpaB and was consistent with a 1:1 complex (Fig. 5B). To unambiguously determine the molecular weight of the complex in solution, we used sedimentation equilibrium analytical centrifugation, as this method can determine the mass of complexes in solution independent of shape. Sedimentation equilibrium analytical centrifugation of the complex peak (Fig. 5C) revealed a molecular mass of  $83.7 \text{ kDa} \pm 4.7 \text{ kDa}$  using a one-component ideal model to assess the molecular mass of the complex in solution (38). The theoretical molecular masses of CpaA and truncated CpaB are 63.1 kDa and 20.4 kDa, respectively. A 1:1 complex of the CpaA and CpaB therefore has a theoretical molecular mass of 83.5 kDa, and the sedimentation equilibrium experiment aligns well with the theoretical molecular mass of a 1:1 complex.


#### The C-terminal domain of CpaB faces the periplasmic space, and its N-terminal transmembrane domain is not required for CpaA secretion

Topological prediction servers and bioinformatic analysis suggest that CpaB has an N-terminal transmembrane domain (28, 29). Therefore, it is likely the C-terminal domain of CpaB that interacts with CpaA. *In vivo*, this interaction could occur in either the cytoplasm or the periplasm. To determine the cell localization of the C-terminal domain of CpaB, we used limited proteolysis of either whole cells or spheroplasts containing CpaB-His, where the hexahistidine tag was added to the C terminus (32, 39). Samples were visualized by Western blot analysis probing for CpaB-His and RNA polymerase as a cytoplasmic control. Whole cells treated with proteinase K have consistent levels of CpaB-His and RNA polymerase over time (Fig. 6A), indicating that CpaB-His is inaccessible to the protease. In contrast, spheroplasts treated with proteinase K show decreasing levels of CpaB-His over time, suggesting that the C-terminal domain is accessible to the protease (Fig. 6B). Furthermore, the consistent levels of RNA polymerase over time indicate that cytoplasmic proteins were sheltered from proteolysis (Fig. 6B). Altogether, these results show that the C terminus of CpaB is periplasmic and suggest that CpaB interacts with CpaA in the periplasm.

To determine whether the N-terminal transmembrane domain of CpaB is required for CpaA secretion, we constructed a soluble periplasmic version of CpaB (CpaB<sub>perIB</sub>-His) by replacing the putative N-terminal transmembrane domain of CpaB-

# Interaction between CpaA and chaperone CpaB





**Figure 6. The C-terminal domain of CpaB is exposed to the periplasmic space.** Shown is a Western blot analysis probing for RNA polymerase as a cytoplasmic control and CpaB-His of samples treated with 0.5  $\mu$ g/ml proteinase K for 0–20 min at 56 °C. *A*, limited proteolysis of M2 whole cells expressing pWH-*cpaB-his*. *B*, limited proteolysis of spheroplasts isolated from M2 cells expressing pWH-*cpaB-his*.

His with the Sec secretion signal of the periplasmic protein PelB from *Escherichia coli*. As expected, CpaB<sub>pelB</sub>-His localized to the periplasm (supplemental Fig. S3). We then transformed M2  $\Delta$ *cpaAB* with FLAG-tagged CpaA and either full-length CpaB-His or CpaB<sub>pelB</sub>-His and probed for the presence of CpaA in cell-free supernatants. CpaA secretion was complemented by either full-length CpaB-His or soluble periplasmic CpaB<sub>pelB</sub>-His (Fig. 7), indicating that CpaB does not need to be membrane-bound to mediate CpaA secretion. Interestingly, soluble CpaB-His was also detected in cell-free supernatants of cells expressing CpaA-FLAG (Fig. 7). To determine whether secretion of the soluble periplasmic chaperone CpaB was CpaA-dependent, we compared secretion of soluble CpaB-His in the presence or absence of CpaA by Western blotting (supplemental Fig. S4). In the absence of CpaA, secretion of soluble CpaB was abrogated, suggesting that soluble periplasmic CpaB is secreted in complex with CpaA (Fig. 6 and supplemental Fig. S4). The minimal amount of soluble CpaB that was secreted in the absence of CpaA could be a consequence of overexpression of soluble CpaB.


#### CpaA is degraded in the absence of CpaB

CpaA is hard to detect in the periplasmic fraction because its secretion is extremely efficient in wild-type *A. nosocomialis* M2. In a  $\Delta$ *cpaB* strain, CpaA was not secreted and, instead, was degraded in the periplasm, as indicated by a CpaA-derived band of ~30 kDa present under these conditions (supplemental Fig. S5). CpaB complementation restored CpaA secretion with the subsequent disappearance of the CpaA proteolytic fragment. This experiment demonstrates that CpaA is not stable in the absence of CpaB.

#### CpaB interaction with CpaA does not completely abolish proteolytic activity against Factor V

CpaA physically interacts with CpaB, and this interaction is required for CpaA secretion (Fig. 4) (28). However, the specific role of CpaB in CpaA secretion remains unclear. CpaA was shown previously to be a secreted metallo-endopeptidase with the ability to degrade human Factor V and thus deregulate blood coagulation (29). One possibility is that this interaction

**Figure 5. CpaA and CpaB form a 1:1 complex in solution.** *A*, size-exclusion chromatography of co-purified CpaA and CpaB reveals a single peak for the CpaA–CpaB complex. *mAu*, milli-absorbance unit. *B*, SDS-PAGE gel of the CpaA–CpaB complex peak reveals two bands that correspond to CpaA and CpaB. *C*, sedimentation equilibrium analytical centrifugation of the size-exclusion-purified CpaA–CpaB complex reveals a 1:1 complex of 83.7 kDa  $\pm$  4.7 kDa. *Top panel*, one-component ideal model fits for one representative experiment of three. *Bottom panel*, the residuals for the one-component ideal model fits for each individual scan.



**Figure 7. Soluble periplasmic CpaB complements a  $\Delta$ *cpaAB* mutant and is secreted with CpaA.** Shown is a Western blot analysis on whole-cell (*W*) and cell-free supernatant (*S*) fractions of  $\Delta$ *cpaAB* M2 expressing empty vector, pWH-*cpaB-his* and pBAV-*cpaA-flag* or pWH-*cpaB<sub>pelB</sub>-his* and pBAV-*cpaA-flag* were probed for CpaB-His. All fractions were probed for RNA polymerase as a lysis control. CpaB-His was detected in all cells carrying pWH-*cpaB-his* or pWH-*cpaB<sub>pelB</sub>-his*. Secretion of CpaB-His was detected in cells carrying pWH-*cpaB<sub>pelB</sub>-his*. CpaA\* is a degradation product from CpaA-FLAG.

inactivates CpaA, preventing self-intoxication of the cell by the proteolytic activity of CpaA (40). To explore the possibility that CpaB is an immunity protein, we compared the proteolytic activity of CpaA alone and in complex with the soluble version of CpaB against human Factor V.


CpaA-His was purified from the cell-free supernatant of mid-log phase *A. nosocomialis* M2, whereas the complex CpaA-FLAG-CpaB<sub>pelB</sub>-His was purified from the supernatant of *A. nosocomialis* M2 $\Delta$ *cpaAB*. For the complex, the hexahistidine tag was placed in CpaB and not in CpaA to ensure that all of the purified CpaA was complexed to CpaB. Cleavage of human Factor V was analyzed by Western blotting, probing for human Factor V and CpaA. Interestingly, CpaA was able to cleave Factor V irrespective of the presence of CpaB (Fig. 8). In contrast, neither heat-inactivated CpaA nor CpaB alone could cleave Factor V (Fig. 7). Although we have not followed the kinetics of this reaction, it can be concluded that CpaB does not completely inhibit CpaA activity against Factor V.

#### Discussion

CpaA is a zinc-dependent metallo-endopeptidase and T2SS substrate of several medically relevant *Acinetobacter* strains (28, 29). Although it is the most abundantly secreted type II substrate in *A. nosocomialis* M2, CpaA is not present in the genomes of typical *Acinetobacter* laboratory strains such as ATCC17978 and ATCC19606 (28). *Acinetobacter* often pres-



## Interaction between CpaA and chaperone CpaB



**Figure 8. CpaA remains catalytically active when complexed with CpaB.** Human Factor V was incubated with purified heat-inactivated CpaA-His, secreted CpaA-His, the secreted CpaA-FLAG-CpaB-His complex, CpaB-His, or buffer (20 mM HEPES and 150 mM NaCl (pH 7.4)) for 30 min at 37 °C. As a positive control, Factor V was mixed with thrombin in 25 mM Tris-HCl, 50 mM NH<sub>4</sub>Cl, and 5 mM CaCl<sub>2</sub> (pH 7.4) at 37 °C for 1 h. The *rightmost* lane represents the buffer control for the thrombin reaction. Full-length Factor V is detectable in the buffer control samples as well as the heat-inactivated CpaA, indicating a lack of proteolysis. The low-molecular-weight bands corresponding to Factor V present in the thrombin lane are indicative of Factor V proteolysis. *a*, heat-inactivated; *b*, CpaA-His; *c*, CpaA-FLAG.

ents as pneumonia; therefore, a murine pulmonary infection was used to study the role of CpaA in lung colonization and dissemination. We showed previously that the T2SS of *A. nosocomialis* M2 was required for full virulence in *G. mellonella* and pulmonary murine models of infection (28). The T2SS-deficient strain did not disseminate to the liver or spleen as efficiently as the wild-type or complemented strains, suggesting that substrates secreted by the T2SS play an important role in *Acinetobacter* virulence. Here we show that CpaA is secreted by multiple clinical isolates of *A. baumannii*, *A. pittii*, and *A. nosocomialis*. Deletion of *cpaA* results in a virulence defect in *G. mellonella* larvae and decreased splenic colonization in a murine pulmonary infection model. The virulence defects resulting from the deletion of *cpaA* are comparable with those observed from the deletion of the T2SS. To our knowledge, CpaA is the first characterized, *bona fide* virulence factor secreted by *Acinetobacter* spp.

Numerous proteins are secreted by *A. nosocomialis* M2 in a type II-dependent manner (28). As mentioned, deletion of *cpaA* has a similar impact on murine splenic colonization and virulence against *G. mellonella* as the loss of type II secretion ( $\Delta$ *gspD*) (Fig. 3). However, unlike the  $\Delta$ *gspD* strain, the  $\Delta$ *cpaA* strain did not show decreased murine lung colonization (Fig. 3) (28). This discrepancy could be attributed to the loss of secretion of all type II substrates in the  $\Delta$ *gspD* strain compared with the single deletion of CpaA in the  $\Delta$ *cpaA* strain. LipA, a confirmed *Acinetobacter* type II substrate, is required for *A. baumannii* competitive murine colonization in a bacteremia model

(27). Therefore, it is plausible that LipA plays a role in murine lung colonization by *A. nosocomialis* and, thus, may partly account for the difference in colonization defect between the  $\Delta$ *gspD* and  $\Delta$ *cpaA* strains. Moreover, CpaA may play a role in dissemination from the initial site of infection in the lungs to a distal site in the spleen. The activity of CpaA against the coagulation factors fibrinogen and Factor V likely contributes to the defect in  $\Delta$ *cpaA* to migrate from the initial infection site.

CpaA is likely translocated to the periplasm by the SecYEG translocation system in an unfolded state (41). When in the periplasm, CpaA must fold to be secreted by the T2SS (8, 42). CpaB is a membrane-anchored protein encoded next to CpaA and is required for CpaA secretion. This is reminiscent of the *B. glumae* type II substrate LipA, which requires a membrane-bound, lipase-specific foldase to be folded into its active form and secreted (33, 34). In this work, we identified additional functional similarities between CpaB and the Lif proteins. We demonstrated that CpaB physically interacts with CpaA. Furthermore, similarly to Lif, the C-terminal globular domain of CpaB is periplasmic and sufficient for CpaA secretion (Fig. 7) (34). Although both chaperones are required for secretion of their cognate substrates, the transmembrane domains of both Lif and CpaB are dispensable for the secretion and proper folding of their respective protein substrates. These results reinforce our suggestion that, although there is absolutely no sequence conservation between CpaB and Lif, these proteins belong to a unique class of type II secretion, membrane-bound chaperones that possess evident functional analogies (28, 33, 34).

We demonstrate that soluble periplasmic CpaB lacking its transmembrane domain is secreted by *A. nosocomialis* M2 complexed with CpaA. This result agrees with a previous study that showed that the T2SS chaperone Lif from *B. glumae* lacking its transmembrane domain (Lifpp) is secreted along with its target lipase. The study also showed that Lifpp secretion was dependent on the expression and secretion of its cognate lipase (34). Altogether, these results suggest that the T2SS substrate-chaperone complex does not dissociate unless the chaperone is anchored to the inner membrane. Dissociation of the T2SS substrate-membrane-anchored chaperone complex is expected to result in type II-dependent secretion of the substrate and retention of the chaperone within the periplasmic space. In the T3SS, the separation of the substrate-chaperone complex is mediated by the ATPase that powers the system (43). How this occurs in the T2SS has yet to be elucidated, but we hypothesize that the membrane anchor in the T2SS chaperone may be involved in retention of the chaperone and disassembly of the complex, possibly through an interaction with the T2SS machinery. The observation that a minimal amount of soluble CpaB is secreted in the absence of CpaA could be the consequence of a hypothetical interaction between CpaB and the T2SS.

Because CpaA is a protease, we hypothesized that CpaB binding might inhibit CpaA activity to protect periplasmic proteins from proteolysis. To this end, we assayed human Factor V cleavage by CpaA alone or in complex with CpaB. We found that CpaB binding to CpaA does not prevent Factor V cleavage, suggesting that CpaB is not primarily an immunity protein. However, we performed an end point assay and thus did not

assess the impact of CpaB binding on the kinetics of CpaA activity. We have not experimentally measured the stability of the CpaA–CpaB complex, but the ability to co-purify the complex and the fact that the complex withstands ultracentrifugation in the analytical ultracentrifugation experiment suggest that the complex between CpaA and CpaB is very stable. However, CpaA and CpaB may still dissociate under our experimental conditions, and the activity we detected may be due to free CpaA. For this reason, we cannot conclude that CpaB binding does not impact CpaA activity but, rather, that the presence of CpaB does not fully prevent CpaA from cleaving human Factor V. Furthermore, CpaA was unstable in the absence of CpaB (supplemental Fig. S5), suggesting that CpaB is involved in folding CpaA into its active, stable, secretion-competent form.

Here we have characterized CpaA as the first *bona fide* virulence factor of the *A. baumannii*–*A. calcoaceticus* complex and provided insight into the molecular interactions between CpaA and its T2SS chaperone CpaB. We have demonstrated that the membrane anchor of CpaB is not required for its chaperone function and further characterized the novel class of T2SS chaperones CpaB represents. We propose that CpaB is involved in folding of CpaA into its active, stable, secretion-competent form. It is plausible that the purpose of the transmembrane domain of CpaB is to retain CpaB in the cell, thus preventing co-secretion of CpaB with CpaA. Future efforts will focus on dissecting whether the membrane anchor facilitates an interaction with either SecYEG or the type II apparatus, yielding more efficient secretion of CpaA. These findings would be beneficial to public health, as elucidation of T2SS substrates and the mechanism of secretion could encourage the development of novel antivirulence treatments for *Acinetobacter* infections, which are particularly troublesome because of increasing rates of multidrug resistance. For instance, specific inhibitors designed to bind and inhibit the activity and/or secretion of a virulence factor are a viable option.

## Experimental procedures

### Strains, plasmids, and growth conditions

The bacterial strains, plasmids, and primers used in this study are listed in supplemental Tables S1 and S2. All strains were grown in LB/agar at 37 °C unless specified otherwise. Antibiotics for *E. coli* selection were used at the following concentrations: 100 µg/ml carbenicillin, 5 µg/ml tetracycline, 12.5 µg/ml chloramphenicol, and 20 µg/ml kanamycin. Antibiotics for *A. nosocomialis* were used at the following concentrations: 20 µg/ml kanamycin, 5 µg/ml tetracycline, 12.5 µg/ml chloramphenicol, and 200 µg/ml carbenicillin. To select for the loss of *sacB*, supplementation with 10% sucrose was used.

### Generation of bacterial mutants and complemented mutants

Unmarked mutations were made using a method published previously (37, 44). The In-Fusion HD EcoDry cloning kit was used in the creation of pGEM-*cpaA::kansacB* and pGEM-*cpaAB::kansacB* knockout plasmids, similarly to Refs. 28, 44. Briefly, 1000 bp upstream of the target gene were amplified with primers 5510015bpkmsacBrev and 5510015bpppgem1fw (or *cpaABK*Oup15bppgemfw2 and *cpaABK*Oup15bpkmsacBrev1),

which produced a product with 15 bp of homology to pGEM at the 5' end and 15 bp of homology to *kmsacB* at the 3' end. 1000 bp downstream of the target gene were amplified with primers 3510015bpkmsacB2fw and 3510015bpppgem2rev (or *cpaABK*Odw15bppgemrev4 and *cpaABK*Odw15bpkmsacBfw3), which produced a product with 15 bp of homology to pGEM at the 3' end and 15 bp of homology to *kmsacB* at the 5' end. The kanamycin resistance cassette and *sacB* gene were amplified using primers *KmsacB*2rev and *KmsacB*1fw. pGEM was amplified using primers *pgem*1rev and *pgem*2fw. The In-Fusion HD EcoDry cloning kit was used to fuse the upstream, downstream, *kmsacB*, and pGEM fragments together, generating pGEM-*cpaA::kmsacB* or pGEM-*cpaAB::kmsacB*. These plasmids were introduced to *A. nosocomialis* through natural transformation (36). The FLP recombinase plasmid pFLP2 was transiently introduced into M2 *cpaA::kmsacB* and M2 *cpaAB::kmsacB* by triparental mating (37) to replace the resistance cassette with an *frt* scar. Strains  $\Delta$ *cpaA* and  $\Delta$ *cpaAB* were verified by PCR and sequencing. The *cpaA* mutation was complemented with the *cpaAB* locus (amplified with primers *kpnIcpaAB*revlocus and *pstIcpaAB*fwlocus and cloned into pRSM4063 at *KpnI* and *PstI*) under its natural putative promoter using the miniTn7 described in Ref. 44. The MiniTn7 complementation construct pRSM4063-*pcpaAB* was introduced into  $\Delta$ *cpaA* through natural transformation as above. Consistent with the nomenclature used by Harding *et al.* (28), mutants designated with “::*frt*” contain an *frt* scar in place of the target gene (28).

### Generation of pWH1266-based constructs

The In-Fusion EcoDry cloning kit was used to create the following constructs: pWH-*cpaA-flag-cpaB-his*, pWH-*cpaA-flag-cpaB*, pWH-*cpaB-his*, and pWH-*cpaB<sub>pelB</sub>-his*. pWH-*cpaA-flag-cpaB-his* was created by fusing *cpaA-flag* (amplified with primers 5cpaAFLAGrev and 3cpaApromfwphw1), pWH1266 (amplified with 2pwhrev1 and 1pwhfw2), and *cpaB-his* (amplified with primers 8CpaBHisrevpwh and 11cpaBfw15bpcpaAF). pWH-*cpaA-flag-cpaB* was created by fusing *cpaA-flag* (amplified with primers 5cpaAFLAG rev and 3cpaApromfwphw1) to pWH1266 (amplified with 2pwhrev1 and 1pwhfw2) and *cpaB* (amplified with CpaBrevNT15bppwh2 and 11cpaBfw15bpcpaAF). pWH-*cpaB-his* was created by fusing the putative promoter of *cpaAB* (amplified with primers 3cpaApromfwphw1 and 6cpaABpromrev), pWH1266, and *cpaB-his* (amplified with primers 8CpaBHisrevpwh and 7CpaBfwpromoverhang). pWH-*cpaB<sub>pelB</sub>-his* was created by fusing pWH1266 to the *cpaAB* promoter to *cpaB<sub>pelB</sub>-his*, where the N-terminal transmembrane domain has been replaced with an N-terminal Sec secretion signal of PelB, (amplified with 8CpaBHisrevpwh and 9CpaBnoTMPelB15bppromfw). All constructs were verified by PCR and sequencing.

### Generation of pBAV-*cpaA-flag*

*CpaA-flag* was PCR amplified with 5100fwbamhl and 5100flagrevpstl and cloned into pBAVMCS at *PstI* and *BamHI*. pBAV-*cpaA-flag* was confirmed by PCR and sequencing.

## Interaction between CpaA and chaperone CpaB

### Generation of pETDuet-*cpaA*-his-*cpaB* and pET28a-cyto-*cpaB*-his

*CpaB* was PCR-amplified with CpaBcytoREV-KpnI and CpaBcytoFwdNdeI and cloned into multiple cloning site 2 at KpnI and NdeI. *CpaA* was cloned into pETDuet using the In-Fusion HD EcoDry cloning kit using petDuetfwinfuse and petDuetrevinfuse to amplify pETDuet-*cpaB* and CpaAcytoFwdNdeI15bp and CpaAcytoHisrevNdeI15bp to amplify *cpaA* with 15 bp of homology to pETDuet. The pETDuet-*cpaA*-his-*cpaB* was confirmed through PCR and sequencing.

Cyto-*cpaB* was PCR-amplified with 15 bp of homology on the 5' and 3' ends to pET28a with CytoCpaBrev and CytoCpaBfw. Cyto-*cpaB* was cloned into pET28a in-frame with the C-terminal histidine tag using the In-Fusion HD EcoDry cloning kit using Pet28ahisfw and Pet28auprev. pET28a-cyto-*cpaB*-his was confirmed by sequencing.

### Generation of polyclonal rabbit sera against CpaA

The pETDuet vector was used to overexpress CpaA and CpaB in the cytoplasm of *E. coli* Rosetta 2 cells for purification. 1 liter of LB was inoculated from an overnight culture of Rosetta 2/pETDuet-*cpaA*-his-*cpaB* at 0.05 A/ml, grown to mid-log phase, and induced with 1 mM isopropyl 1-thio- $\beta$ -D-galactopyranoside. The culture was grown for an additional 4 h. Cells were harvested at 8000 rpm for 10 min. Cells were washed with 30 mM Tris (pH 8) and resuspended in 40 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 10 mM imidazole (pH 8). Cells were lysed with a cell disruptor using two rounds at 35,000 p.s.i. (Constant System Ltd., Kennesaw, GA). Cell lysates were clarified at 11,000 rpm for 30 min. Cell lysates were passed over a nickel-NTA agarose column (Gold Bio, St. Louis, MO). The load fraction is the total cell lysate. The flow-through was collected as what passed through the column and did not bind the nickel-NTA resin. The column was washed with 20 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 25 mM imidazole (pH 8) and 20 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 50 mM imidazole (pH 8) (45). Proteins were eluted with 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 250 mM imidazole (pH 8). Elution fractions were analyzed by SDS-PAGE analysis and Coomassie staining. The polyacrylamide gel band corresponding to CpaA-His was sent to Abore Inc. (Ramona, CA) for peptide extraction and development of rabbit-derived polyclonal antibodies.

### Nickel-NTA affinity purification of CpaB-His and CpaA-FLAG

Cultures of M2  $\Delta$ *cpaAB* carrying pWH-*pCpaA-flag-cpaB*-his, pWH-*pCpaA-flag-cpaB*, or pWH1266 were grown overnight. Cells were pelleted at 10,000  $\times$  g for 10 min. Cells were washed with 30 mM Tris (pH 8) and resuspended in 15 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 10 mM imidazole (pH 8). Cells were lysed with a cell disruptor using two rounds at 35,000 p.s.i. (Constant System Ltd.). Cell lysates were incubated with 0.05% Triton X-100 and rolling at 4 °C for 1 h to solubilize CpaB-His (46). Cell lysates were clarified at 11,000 rpm for 30 min. Cell lysates were passed over a nickel-NTA-agarose column (Gold Bio). The load fraction is the total cell lysate. The flow-through was collected as what passed through the column and did not bind the nickel-NTA resin. The column was washed with 20 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 25 mM imidazole (pH 8)

and 20 ml of 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 50 mM imidazole (pH 8) (45). Proteins were eluted with 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, and 250 mM imidazole (pH 8). Load, flow-through, wash, and elution fractions were analyzed by Western blot analysis probing for CpaA-FLAG and CpaB-His.

### Size-exclusion purification of CpaA and CpaB

CpaA-His and CpaB were co-purified from *E. coli* Rosetta 2 cells by nickel-NTA resin as described above. The nickel-NTA elution was further purified by a Superdex 200 Prepgrade size-exclusion column (GE Healthcare) with 10 mM HEPES (pH 7.4) and 150 mM NaCl. The fractions under the CpaA-CpaB complex peak were concentrated using an Amicon Ultra centrifugal filter (Millipore) with a 10-kDa molecular mass cutoff.

### Analytical ultracentrifugation of the CpaA-CpaB complex

Sedimentation equilibrium experiments were performed in a Beckman/Coulter XL-A analytical ultracentrifuge using an An60Ti rotor at 10 °C with size-exclusion-purified CpaA-CpaB complex at concentrations of 4.2  $\mu$ M, 3.4  $\mu$ M, and 2.5  $\mu$ M. Data were obtained at speeds of 7000, 8000, and 9000 rpm. A partial specific volume for CpaA-CpaB of 0.7321 was calculated with Sednterp (47), and a global fit analysis was performed in Ultrascan II version 9.9 (38). The molecular mass reported is the mean  $\pm$  S.D. of the three independent experiments at all concentrations and speeds analyzed.

### CpaB-His localization and limited proteolysis of *A. nosocomialis* M2 spheroplasts

Overnight cultures of *A. nosocomialis* M2 carrying pWH-*cpaB*-his or pWH-*cpaB<sub>pelB</sub>*-his were used to inoculate LB supplemented with tetracycline that were grown at 37 °C and 225 rpm. Periplasmic and spheroplast preparations were done as reported previously (39). Briefly, cultures grown to 0.5 A/ml were pelleted by centrifugation at 10,000 rpm for 10 min. Cells were resuspended at 1 A/50  $\mu$ l in 20% sucrose, 30 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 1 mg/ml lysozyme (Gold Bio) and incubated on ice for 2 h. Spheroplasts were pelleted at 16,000  $\times$  g for 5 min. The supernatant fraction was considered the periplasmic fraction. For CpaB-His localization, periplasmic and spheroplast fractions were analyzed by SDS-PAGE and immunoblotting. Proteolysis of spheroplasts was performed as follows. Spheroplasts were resuspended at 0.01 A/ $\mu$ l in 0.5 mg/ml proteinase K (Sigma) in 30 mM Tris-HCl (pH 8.0) and incubated at 56 °C for 0–20 min. Protease activity was stopped by the addition phenylmethylsulfonyl fluoride and 4 $\times$  Laemmli buffer and boiling at 100 °C. The equivalent of 0.1 A of each sample was resolved by SDS-PAGE and analyzed by Western blotting, probing for CpaB-His and RNA polymerase as a cytoplasmic control.

### Immunoblotting

Bacterial secretion whole-cell and supernatant samples were prepared as published previously (28, 48). Briefly, cultures were grown to 0.5 A/ml, and 0.5 A was pelleted by centrifugation and resuspended in 50  $\mu$ l of 1 $\times$  Laemmli buffer for the whole-cell samples. Supernatant samples were obtained by TCA-precipitating cell-free supernatants as published previously (48). Pro-

teins were resolved by SDS-PAGE analysis and transferred to a nitrocellulose membrane by semidry transfer and probed with either monoclonal anti-FLAG (1:2000, Sigma), polyclonal anti-histidine (1:2000, Pierce), polyclonal anti-CpaA (1:1000, this study), and/or monoclonal anti-RNA polymerase (1:2000, Neoclone). Western blots were probed with IRDye-conjugated secondary antibodies and visualized with an Odyssey CLx imaging system (LI-COR Biosciences, Lincoln, NE).

### G. mellonella infection

*G. mellonella* infections with *A. nosocomialis* M2,  $\Delta$ *gspD*::*frt*,  $\Delta$ *cpaA*::*frt*, and the complemented strains were done as published previously (28). Cultures were grown in LB to 0.5 A/ml. Cells were pelleted by centrifugation, washed with sterile PBS, and resuspended in PBS. *G. mellonella* were injected with 10  $\mu$ l of either M2,  $\Delta$ *gspD*::*frt*,  $\Delta$ *cpaA*, or the complemented strains at an inoculum of  $1 \times 10^7$ . Infected larvae were incubated at 37 °C and monitored for viability over time. Larvae were considered dead when they did not respond to touch.

### Mouse model of pneumonia

The Vanderbilt University Medical Center Institutional Animal Care and Use Committee approved the infection experiments. Jackson Laboratories wild-type C57BL/6 mice were infected with either the  $\Delta$ *cpaA* or the *cpaA*+ complemented strain as published previously (28). Nine-week-old male mice were inoculated intranasally with  $1 \times 10^9$  cfus. Thirty-six hours post-infection, mice were euthanized, and lung, liver, spleen, and heart tissues were homogenized and dilution-plated to determine colony-forming units. Median colony-forming unit counts from each mouse are reported and were analyzed by Mann Whitney non-parametric tests using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA).

### Factor V cleavage assay

CpaA-His or CpaA-FLAG-CpaB<sub>pelB</sub>-His was purified out of the supernatant of *A. nosocomialis* M2. Briefly, *A. nosocomialis* M2 carrying pWH-*cpaA-his-cpaB* or *A. nosocomialis*  $\Delta$ *cpaAB*::*frt* carrying both pBAV-*cpaA-flag* and pWH-*cpaB<sub>pelB</sub>-his* was grown in LB supplemented with tetracycline or kanamycin and tetracycline to mid-log phase. CpaA-His or the CpaA-FLAG-CpaB<sub>pelB</sub>-His complex was purified from cell-free supernatants through nickel affinity chromatography as above. CpaB-His was purified from cell lysate of *E. coli* Rosetta 2 cells carrying pET28-*cpaB-his*. Cells were grown overnight at 30 °C and 225 rpm in autoinduction medium supplemented with kanamycin. Cells were harvested and lysed as described above. CpaB-His was purified by nickel affinity chromatography as above. The purified proteins were concentrated, and the buffer was changed to 20 mM HEPES, 150 mM NaCl, and 50% glycerol (pH 7.4) using Amicon Ultra centrifugal filter units.

The Factor V cleavage assay was carried out according to Tilley *et al.* (29) with modifications. Briefly, 1.6  $\mu$ g of purified CpaA or CpaB (in 20 mM HEPES, 150 mM NaCl, and 50% glycerol (pH 7.4)) was mixed with 11 ng of human Factor V (Abcam, Cambridge, MA) in a total volume of 20  $\mu$ l (20 mM HEPES and 150 mM NaCl (pH 7.4)). Heat-inactivated CpaA was incubated at 100 °C for 20 min prior to the addition of Factor V. Based on

Coomassie staining indicating that CpaA and CpaB form a 1:1 complex, 3.2  $\mu$ g of the CpaA–CpaB complex was used in the assay, which is estimated to contribute  $\sim$ 1.6  $\mu$ g of CpaA. All samples were incubated at 37 °C for 30 min.

$\alpha$ -Thrombin was used as a positive control in the proteolytic cleavage of Factor V (49). The thrombin-catalyzed digestion of FV was carried out as described previously (50) with modifications. Briefly, 0.6 mg/ml human Factor V and 2  $\mu$ g/ml of  $\alpha$ -thrombin (Thermo Fisher, Waltham, MA) in 25 mM Tris-HCl (pH 7.4), 50 mM NH<sub>4</sub>Cl, and 5 mM CaCl<sub>2</sub> was incubated at 37 °C for 60 min. The buffer control for this reaction was carried out in the same way but in the absence of  $\alpha$ -thrombin.

Factor V cleavage was monitored by Western blotting by resolving 8.2 ng of Factor V per lane on an 8% polyacrylamide gel. Factor V was detected using polyclonal sheep anti-human Factor V (Thermo Fisher, 1:1000), polyclonal rabbit anti-sheep Ig (Fc-specific, Sigma-Aldrich, St. Louis, MO, 1:12,000), and IRDYE®800CW goat anti-rabbit IgG (LI-COR, 1:15,000). CpaA-His was detected with monoclonal mouse anti-His<sub>6</sub> (Thermo Fisher, 1:1000) and IRDYE®680RD goat anti-mouse IgG (LI-COR, 1:15,000), whereas CpaA-FLAG was detected using monoclonal mouse anti-FLAG M2 (Sigma-Aldrich, 1:1000) and IRDYE®680RD goat anti-mouse IgG (LI-COR).

**Author contributions**—The experiments were designed by R. L. K. under the guidance of M. F. F. The mouse infection experiment was designed and performed by L. D. P. under the guidance of E. P. S. The Factor V cleavage assay was performed by J. L. N. D. S. performed the size-exclusion chromatography and analytical ultracentrifugation experiments under the guidance of N. H. T. All other experiments were performed by R. L. K. The manuscript was written by R. L. K., J. L., and M. F. F. All authors edited the manuscript.


**Acknowledgment**—We thank M. Florencia Haurat for assistance with protein purification.

### References


1. DebRoy, S., Dao, J., Söderberg, M., Rossier, O., and Cianciotto, N. P. (2006) *Legionella pneumophila* type II secretome reveals unique exoproteins and a chitinase that promotes bacterial persistence in the lung. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 19146–19151
2. Fujieda, M., Aoyagi, Y., Matsubara, K., Takeuchi, Y., Fujimaki, W., Matsushita, M., Bohnsack, J. F., and Takahashi, S. (2012) L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci. *Infect. Immun.* **80**, 2053–2060
3. McCoy-Simandle, K., Stewart, C. R., Dao, J., DebRoy, S., Rossier, O., Bryce, P. J., and Cianciotto, N. P. (2011) *Legionella pneumophila* type II secretion dampens the cytokine response of infected macrophages and epithelia. *Infect. Immun.* **79**, 1984–1997
4. Sandkvist, M., Morales, V., and Bagdasarian, M. (1993) A protein required for secretion of cholera toxin through the outer membrane of *Vibrio cholerae*. *Gene* **123**, 81–86
5. Sikora, A. E., Zielke, R. A., Lawrence, D. A., Andrews, P. C., and Sandkvist, M. (2011) Proteomic analysis of the *Vibrio cholerae* type II secretome reveals new proteins, including three related serine proteases. *J. Biol. Chem.* **286**, 16555–16566
6. Ho, T. D., Davis, B. M., Ritchie, J. M., and Waldor, M. K. (2008) Type 2 secretion promotes enterohemorrhagic *Escherichia coli* adherence and intestinal colonization. *Infect. Immun.* **76**, 1858–1865
7. Jyot, J., Balloy, V., Jouvion, G., Verma, A., Touqui, L., Huerre, M., Chignard, M., and Ramphal, R. (2011) Type II secretion system of *Pseudomo-*

## Interaction between CpaA and chaperone CpaB


- nas aeruginosa*: *in vivo* evidence of a significant role in death due to lung infection. *J. Infect. Dis.* **203**, 1369–1377
8. Costa, T. R., Felisberto-Rodrigues, C., Meir, A., Prevost, M. S., Redzej, A., Trokter, M., and Waksman, G. (2015) Secretion systems in Gram-negative bacteria: structural and mechanistic insights. *Nat. Rev. Microbiol.* **13**, 343–359
  9. Nivaskumar, M., and Francetic, O. (2014) Type II secretion system: a magic beanstalk or a protein escalator. *Biochim. Biophys. Acta* **1843**, 1568–1577
  10. Sandkvist, M. (2001) Biology of type II secretion. *Mol. Microbiol.* **40**, 271–283
  11. Sandkvist, M. (2001) Type II secretion and pathogenesis. *Infect. Immun.* **69**, 3523–3535
  12. Pineau, C., Guschinskaya, N., Robert, X., Gouet, P., Ballut, L., and Shevchik, V. E. (2014) Substrate recognition by the bacterial type II secretion system: more than a simple interaction. *Mol. Microbiol.* **94**, 126–140
  13. McLaughlin, L. S., Haft, R. J., and Forest, K. T. (2012) Structural insights into the type II secretion nanomachine. *Curr. Opin. Struct. Biol.* **22**, 208–216
  14. Yan, Z., Yin, M., Xu, D., Zhu, Y., and Li, X. (2017) Structural insights into the secretin translocation channel in the type II secretion system. *Nat. Struct. Mol. Biol.* **24**, 177–183
  15. World Health Organization (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.
  16. Park, Y. K., Jung, S. I., Park, K. H., Kim, S. H., and Ko, K. S. (2012) Characteristics of carbapenem-resistant *Acinetobacter* spp. other than *Acinetobacter baumannii* in South Korea. *Int. J. Antimicrob. Agents* **39**, 81–85
  17. Chusri, S., Chongsuivatwong, V., Rivera, J. I., Silpapojakul, K., Singkhaman, K., McNeil, E., and Doi, Y. (2014) Clinical outcomes of hospital-acquired infection with *Acinetobacter nosocomialis* and *Acinetobacter pittii*. *Antimicrob. Agents Chemother.* **58**, 4172–4179
  18. Wendt, C., Dietze, B., Dietz, E., and Rüdén, H. (1997) Survival of *Acinetobacter baumannii* on dry surfaces. *J. Clin. Microbiol.* **35**, 1394–1397
  19. Tomaras, A. P., Dorsey, C. W., Edelmann, R. E., and Actis, L. A. (2003) Attachment to and biofilm formation on abiotic surfaces by *Acinetobacter baumannii*: involvement of a novel chaperone-usher pili assembly system. *Microbiology* **149**, 3473–3484
  20. Howard, A., O'Donoghue, M., Feeney, A., and Sleator, R. D. (2012) *Acinetobacter baumannii*. *Virulence* **3**, 243–250
  21. Espinal, P., Martí, S., and Vila, J. (2012) Effect of biofilm formation on the survival of *Acinetobacter baumannii* on dry surfaces. *J. Hosp. Infect.* **80**, 56–60
  22. Cisneros, J. M., and Rodríguez-Baño, J. (2002) Nosocomial bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical features and treatment. *Clin. Microbiol. Infect.* **8**, 687–693
  23. Bergogne-Bérézin, E., and Towner, K. J. (1996) *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin. Microbiol. Rev.* **9**, 148–165
  24. Valencia, R., Arroyo, L. A., Conde, M., Aldana, J. M., Torres, M.-J., Fernández-Cuenca, F., Garnacho-Montero, J., Cisneros, J. M., Ortíz, C., Pachón, J., and Aznar, J. (2009) Nosocomial outbreak of infection with pan-drug-resistant *Acinetobacter baumannii* in a tertiary care university hospital. *Infect. Control Hosp. Epidemiol.* **30**, 257–263
  25. Fournier P. E., Richet, H., and Winstein, R. A. (2006) The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin. Infect. Dis.* **42**, 692–699
  26. Eijkelkamp, B. A., Stroehrer, U. H., Hassan, K. A., Paulsen, I. T., and Brown, M. H. (2014) Comparative analysis of surface-exposed virulence factors of *Acinetobacter baumannii*. *BMC Genomics* **15**, 1020
  27. Johnson, T. L., Waack, U., Smith, S., Mobley, H., and Sandkvist, M. (2015) *Acinetobacter baumannii* is dependent on the type II secretion system and its substrate LipA for lipid utilization and *in vivo*. *J. Bacteriol.* **198**, 711–719
  28. Harding, C. M., Kinsella, R. L., Palmer, L. D., Skaar, E. P., and Feldman, M. F. (2016) Medically relevant *Acinetobacter* species require a type II secretion system and specific membrane-associated chaperones for the export of multiple substrates and full virulence. *PLoS Pathog.* **12**, e1005391
  29. Tilley, D., Law, R., Warren, S., Samis, J. A., and Kumar, A. (2014) CpaA a novel protease from *Acinetobacter baumannii* clinical isolates deregulates blood coagulation. *FEMS Microbiol. Lett.* **356**, 53–61
  30. Kessler, E., and Safrin, M. (1994) The propeptide of *Pseudomonas aeruginosa* elastase acts as an elastase inhibitor. *J. Biol. Chem.* **269**, 22726–22731
  31. Shinde, U., and Inouye, M. (2000) Intramolecular chaperones: polypeptide extensions that modulate protein folding. *Semin. Cell Dev. Biol.* **11**, 35–44
  32. Frenken, L. G., Bos, J. W., Visser, C., Müller, W., Tommassen, J., and Verrips, C. T. (1993) An accessory gene, lipB, required for the production of active *Pseudomonas glumae* lipase. *Mol. Microbiol.* **9**, 579–589
  33. Rosenau, F., Tommassen, J., and Jaeger, K. E. (2004) Lipase-specific foldases. *ChemBioChem* **5**, 152–161
  34. El Khattabi M., Ockhuijsen C., Bitter W., Jaeger K. E., and Tommassen, J. (1999) Specificity of the lipase-specific foldases of gram-negative bacteria and the role of the membrane anchor. *Mol. Gen. Genet.* **261**, 770–776
  35. Page, A. L., and Parsot, C. (2002) Chaperones of the type III secretion pathway: jacks of all trades. *Mol. Microbiol.* **46**, 1–11
  36. Harding, C. M., Tracy, E. N., Carruthers, M. D., Rather, P. N., Actis, L. A., and Munson, R. S., Jr. (2013) *Acinetobacter baumannii* strain M2 produces Type IV Pili which play a role in natural transformation and twitching motility but not surface-associated motility. *MBio* **4**, e00360-13
  37. Carruthers M. D., Nicholson P. A., Tracy E. N., and Munson R. S. (2013) *Acinetobacter baumannii* utilizes a type VI secretion system for bacterial competition. *PLoS ONE* **8**, e59388
  38. Demeler B. (2005) in *Modern Analytical Ultracentrifugation: Techniques and Methods* (Scott, D.J., Harding, S.E., and Rowe, A.J., eds.) pp. 210–219, Royal Society of Chemistry, Cambridge, UK
  39. Feldman, M. F., Wacker, M., Hernandez, M., Hitchen, P. G., Marolda, C. L., Kowarik, M., Morris, H. R., Dell, A., Valvano, M. A., and Aebi, M. (2005) Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 3016–3021
  40. Weber, B. S., Kinsella, R. L., Harding, C. M., and Feldman, M. F. (2017) The secrets of *Acinetobacter* secretion. *Trends Microbiol.* **25**, 532–545
  41. Green E. R., and Mecsas J. (2016) Bacterial secretion systems: an overview. *Microbiol. Spectr.* **4**, 10.1128/microbiolspec.VMBF-0012-2015
  42. Filloux, A. (2004) The underlying mechanisms of type II protein secretion. *Biochim. Biophys. Acta* **1694**, 163–179
  43. Akeda, Y., and Galán, J. E. (2005) Chaperone release and unfolding of substrates in type III secretion. *Nature* **437**, 911–915
  44. Harding, C. M., Nasr, M. A., Kinsella, R. L., Scott, N. E., Foster, L. J., Weber, B. S., Fiester, S. E., Actis, L. A., Tracy, E. N., Munson, R. S., Jr., and Feldman, M. F. (2015) *Acinetobacter* strains carry two functional oligosaccharyl-transferases, one devoted exclusively to type IV pilin, and the other one dedicated to O-glycosylation of multiple proteins. *Mol. Microbiol.* **96**, 1023–1041
  45. Bornhorst, B. J. A., and Falke, J. J. (2000) Purification of proteins using polyhistidine affinity tags. *Methods Enzymol.* **326**, 245–254
  46. Schnaitman, C. A. (1971) Effect of ethylenediaminetetraacetic acid, Triton X-100, and lysozyme on the morphology and chemical composition of isolated cell walls of *Escherichia coli*. *J. Bacteriol.* **108**, 553–563
  47. Laue T. M., Shah B. D., Ridgeway T. M., and Pelletier S. L. (1992) in *Analytical Ultracentrifugation in Biochemistry and Polymer Science* (Harding, S. E., Rowe, A. J., and Horton, J. C., Horton, eds.), pp. 90–125, Cambridge Royal Society of Chemistry, Cambridge, UK
  48. Weber B. S., Miyata S. T., Iwashiki J. A., Mortensen B. L., Skaar E. P., Pukatzki S., and Feldman M. F. (2013) Genomic and functional analysis of the type VI secretion system in *Acinetobacter*. *PLoS ONE* **8**, e55142
  49. Camire, R. M., and Bos, M. H. (2009) The molecular basis of Factor V and VIII procofactor activation. *J. Thromb. Haemost.* **7**, 1951–1961
  50. Suzuki, K., Dahlbäck, B., and Stenflo, J. (1982) Thrombin-catalyzed activation of human coagulation Factor V. *J. Biol. Chem.* **257**, 6556–6564




**Figure S1-A. *nosocomialis* CpaA Secretion is Dependent upon *cpaA*.** Supernatants from wildtype M2,  $\Delta cp a A$ , and the complemented strains (*cpaA*+) were analyzed by Western blot analysis probing for CpaA and RNA polymerase for secretion of CpaA. CpaA is detected in the supernatants of wildtype M2 and the complemented  $\Delta cp a A$  strain, indicating CpaA secretion is dependent upon *cpaA*. RNA polymerase was used as a lysis control. RNA polymerase is not detected; indicating CpaA is actively secreted by *A. nosocomialis*.




**Figure S2- M2 CpaB is Required for Secretion of CpaA-His but Deletion of *cpaA* and *cpaB* does Not Affect Secretion of Type II Substrate LipH-His.** Western blot analysis on whole cell (W) and cell free supernatant (S) fractions of (A) wildtype M2 or (B)  $\Delta cp a A B$  M2 expressing empty vector, pWH-*lipH-his*, pWH-*cpaA-his*, or pWH-*cpaA-hiscpaB* probing for CpaA-His or LipH-His. All strains and fractions were probed for RNA polymerase as a cell lysis control. CpaA-His secretion was detected in strains carrying pWH-*cpaA-his* or pWH-*cpaA-hiscpaB*. CpaA-His secretion was only detected in cells expressing *cpaB*. LipH-His expression and secretion was detected in cells carrying pWH-*lipH-his*. CpaA and CpaB are not required for secretion of type II substrate LipH. CpaB is required for secretion of CpaA.



**Figure S3- Replacement of the N-terminal Transmembrane Domain of CpaB with a Sec Secretion Signal Results in a Soluble Periplasmic Construct of CpaB.** Western blot analysis on M2 cells fractionated into the periplasm (peri) or spheroplast (sphero) expressing empty vector, pWH-*cpaB-his* or pWH-*cpaB<sub>pelB</sub>-his* probing for CpaB-His and RNA polymerase as a lysis control. CpaB-His is detected in the spheroplast fraction of the cells expressing full length CpaB. CpaB-His is detected in the spheroplast and periplasmic fractions of cells expressing the soluble *cpaB<sub>pelB</sub>* construct where the N-terminal transmembrane domain has been replaced with a Sec secretion signal.



**Figure S4- CpaA is Required for Efficient Secretion of Soluble Periplasmic CpaB.** Western blot analysis on whole cell (W) and cell free supernatant (S) fractions of  $\Delta$ *cpaAB* M2 expressing empty vector, pWH-*cpaB-his*, pWH-*cpaB<sub>pelB</sub>-his* or pWH-*cpaB<sub>pelB</sub>-his* and pBAV-*cpaA-flag* was probed for CpaB-His. All fractions were probed for RNA polymerase as a lysis control. CpaB-His was detected in all cells carrying pWH-*cpaB-his* or pWH-*cpaB<sub>pelB</sub>-his*. A low level of CpaB-His secretion was detected in the absence of CpaA in cells carrying pWH-*cpaB<sub>pelB</sub>-his*. Cells carrying pBAV-*cpaA-flag* efficiently secreted CpaB-His when compared to cells devoid of CpaA.



**Figure S5-CpaA is Unstable and Degraded in the Periplasm in the Absence of CpaB.** Whole cells (WC), spheroplasts (sphero), periplasmic (peri) and supernatant (sup) preparations of *A. nosocomialis* M2 wildtype (wt),  $\Delta cpdB$  mutant, and *cpdB+* complemented strains were analyzed by Western blot using anti-CpaA polyclonal antibodies. RNA polymerase was used as a lysis control. The asterisk indicates the proteolytic fragment derived from CpaA.



**Supplemental Table 1**

Plasmids and bacterial strains used in this study

Description	Source
<b>Plasmids</b>	
pBAVMCS	(50)
pBAV- <i>cpaA-flag</i>	This study
pET28a	Novagen
pET28a- <i>cpaB-his</i>	This study
pETDUET	Novagen
pETDUET- <i>cpaA-his-CpaB</i>	This study
pFLP2	(51)
pGEM- <i>cpaA::kansacB</i>	This study
pGEM- <i>cpaAB::kansacB</i>	This study
pRSM4063	(44)
pRSM4063- <i>pcpaA</i>	This study
pWH1266	(52)
pWH- <i>cpaA-his</i>	(28)
pWH- <i>cpaA-his-cpaB</i>	(28)
pWH- <i>lipH-his</i>	(28)
pWH- <i>cpaA-flag-cpaB</i>	This study
pWH- <i>cpaA-flag-cpaB-his</i>	This study
pWH- <i>cpaB-his</i>	This study
pWH- <i>cpaB-pelB-his</i>	This study
<b>Strains</b>	
<i>A. nosocomialis</i> M2	(38, 53)
<i>A. nosocomialis</i> M2 $\Delta$ <i>gspD::frt</i>	(28)
<i>A. nosocomialis</i> M2 $\Delta$ <i>cpaB::frt</i>	(28)
<i>A. nosocomialis</i> M2 $\Delta$ <i>cpaA::frt</i>	This study
<i>A. nosocomialis</i> M2 $\Delta$ <i>cpaAB::frt</i>	This study
<i>A. nosocomialis</i> M2 $\Delta$ <i>cpaA::frt</i> ( <i>cpaAB+</i> )	This study
<i>E. coli</i> Rosetta 2	Novagen
<i>A. baumannii</i> RUH134	(54)
<i>A. baylyi</i> ADPI	(55)
<i>A. baumannii</i> SDF	(56)
<i>A. baumannii</i> AYE	(56)
<i>A. baumannii</i> AB5075	(57)
<i>A. baumannii</i> AB04	(58)
<i>A. baumannii</i> AB004	(29)
<i>A. baumannii</i> AB005	(29)
<i>A. baumannii</i> AB006	(29)
<i>A. baumannii</i> AB007	(29)
<i>A. baumannii</i> AB008	(29)
<i>A. baumannii</i> AB009	(29)
<i>A. baumannii</i> AB010	(29)
<i>A. baumannii</i> AB011	(29)
<i>A. baumannii</i> AB012	(29)
<i>A. baumannii</i> AB013	(29)

<i>A. baumannii</i> AB014	(29)
<i>A. baumannii</i> AB033	(29)
<i>A. baumannii</i> AB034	(29)
<i>A. baumannii</i> AB028	(29)
<i>A. pittii</i> 31205	(59)
<i>A. calcoaceticus</i> 27693	(59)
<i>A. pittii</i> 28207	(59)
<i>A. pittii</i> 30005	(59)
<i>A. pittii</i> 31975	(59)
<i>A. pittii</i> 31357	(59)
<i>A. pittii</i> 33632	(59)
<i>A. pittii</i> 32493	(59)
<i>A. nosocomialis</i> 26959	(59)
<i>A. nosocomialis</i> 33904	(59)

---

Primers used in this study

Description	Sequence
petDuetfwinfuse	GA <sub>2</sub> T <sub>2</sub> CGAGCTCG <sub>2</sub> (CG) <sub>2</sub> C <sub>2</sub> TGCAG
petDuetrevinfuse	GCTGC <sub>3</sub> ATG <sub>2</sub> (TA) <sub>2</sub> TCTC <sub>2</sub> T <sub>2</sub> C
CpaBcytorevKpnI	(AT) <sub>2</sub> G <sub>2</sub> TAC <sub>3</sub> TATG <sub>2</sub> ATGATC(ATG) <sub>2</sub> TA <sub>2</sub> CTC <sub>2</sub>
CpaBcytofwNdeI	(AT) <sub>2</sub> C(AT) <sub>2</sub> GATGCAGCA <sub>3</sub> GT <sub>2</sub> CT <sub>2</sub> CTGCT <sub>3</sub> A <sub>2</sub> CG
CpaAcytofwduet15bp	(TA) <sub>2</sub> C <sub>2</sub> ATG <sub>3</sub> CAGCATG <sub>2</sub> CA <sub>2</sub> C <sub>2</sub> GACTGT(CA) <sub>2</sub> A <sub>3</sub> TCAG
CpaAcytoHisrevduet15bp	GC <sub>2</sub> GAGCTCGA <sub>2</sub> T <sub>2</sub> CT <sub>2</sub> AGTG <sub>2</sub> TGATGATG <sub>2</sub> TGATG <sub>2</sub> T <sub>2</sub> A(TA) <sub>2</sub> (GA) <sub>2</sub> A <sub>2</sub> T <sub>6</sub> GTGC
5100fwbamhI	(AT) <sub>2</sub> G <sub>2</sub> ATC <sub>2</sub> ATG <sub>2</sub> TGA <sub>2</sub> T <sub>4</sub> A <sub>3</sub> T <sub>2</sub> A <sub>5</sub> CATCAC
5100flagrevpstI	(AT) <sub>2</sub> CTGCAGT <sub>2</sub> ACT <sub>2</sub> ATCGTCGTCATC <sub>2</sub> T <sub>2</sub> GTA <sub>2</sub> TCGT <sub>2</sub> ATATAG AGA <sub>3</sub> T <sub>6</sub> GTG
Kmsacb2rev	TGTAG <sub>2</sub> CTG <sub>2</sub> AGCTGCT <sub>2</sub> CG
Kmsacb1fw	AT <sub>2</sub> C <sub>2</sub> G <sub>4</sub> ATC <sub>2</sub> GTTCGAC <sub>2</sub>
3510015bppgem2rev	(CG) <sub>2</sub> A <sub>2</sub> T <sub>2</sub> CACTAGTCGC <sub>2</sub> T <sub>2</sub> GCAG <sub>2</sub> T <sub>2</sub> G(CA) <sub>2</sub> GACT <sub>2</sub> CAC
3510015bpkmsacB2fw	CAGCTC <sub>2</sub> AGC <sub>2</sub> TACATA <sub>2</sub> T(CT) <sub>2</sub> AT <sub>5</sub> AGCTGTA <sub>3</sub> TA <sub>2</sub> TG
5510015bpkmsacBrev	ACG <sub>2</sub> ATC <sub>4</sub> G <sub>2</sub> A <sub>2</sub> T(CA) <sub>2</sub> GTAG <sub>2</sub> TCT <sub>4</sub> AT <sub>3</sub> GT <sub>5</sub> AG
5510015bppgem1fw	C <sub>2</sub> G <sub>2</sub> C <sub>2</sub> GC <sub>2</sub> ATG <sub>2</sub> CGACGC <sub>2</sub> A <sub>2</sub> TGAT <sub>2</sub> GATCTG <sub>2</sub> A <sub>2</sub> T <sub>2</sub> G
6cpaABpromrev	AGTAGC <sub>2</sub> TCT <sub>4</sub> AT <sub>3</sub> GT <sub>5</sub> AGAT <sub>4</sub> CG
5CpaAFLAGrev	T <sub>2</sub> ACT <sub>2</sub> ATC(GTC) <sub>2</sub> ATC <sub>2</sub> T <sub>2</sub> GTA <sub>2</sub> TCGT(TA) <sub>3</sub> (GA) <sub>2</sub> A <sub>2</sub> T <sub>6</sub> GTGC
3cpaApromfwphw1	(ACT) <sub>2</sub> CTGACA <sub>2</sub> CGATCGCTA(TC) <sub>2</sub> AGC <sub>2</sub> AT <sub>3</sub> GT <sub>3</sub> CT <sub>2</sub> C <sub>2</sub> TG
2Pwhrev1	T <sub>2</sub> GTCAGA <sub>2</sub> GTA <sub>2</sub> GT <sub>2</sub> G <sub>2</sub> C <sub>2</sub> G
1Pwhfw2	GAG <sub>2</sub> AC <sub>2</sub> GA <sub>2</sub> G <sub>2</sub> AGCTA <sub>2</sub> C <sub>2</sub> GC
9CpaBnoTmpeI15bppromfw	ATA <sub>4</sub> GAG <sub>2</sub> CTACTCGATCGATGA <sub>3</sub> TAC <sub>2</sub> (TGC) <sub>2</sub> CGAC <sub>2</sub> (GCT) <sub>3</sub> G <sub>2</sub> T C(TGC) <sub>2</sub> TC <sub>2</sub> TCGCTGC <sub>3</sub> AGC <sub>2</sub> G <sub>2</sub> CGATG <sub>2</sub> C <sub>2</sub> ATGT(CA) <sub>2</sub> GCA <sub>3</sub> GT <sub>2</sub> C T <sub>2</sub> CTGCT <sub>3</sub> A <sub>2</sub> CG
8CpaBHisrevpwh2	GCTC <sub>2</sub> T <sub>2</sub> CG <sub>2</sub> (TC) <sub>2</sub> GATCGCTA <sub>2</sub> (TGA) <sub>2</sub> (TGG) <sub>3</sub> TG(ATG) <sub>2</sub> TG <sub>2</sub> ATG ATC(ATG) <sub>2</sub> TA <sub>2</sub> CTC <sub>2</sub> TG
7CpaBfwpromoverhang	ATA <sub>4</sub> GAG <sub>2</sub> CTACT <sub>2</sub> CTCTAT <sub>5</sub> AGCTGTA <sub>3</sub> TA <sub>2</sub> TGA <sub>2</sub> G
11CpaBfw15bpcpaAF	(GAC) <sub>2</sub> GATA <sub>2</sub> GTA <sub>2</sub> T <sub>2</sub> (CT) <sub>2</sub> AT <sub>5</sub> AGCTGTA <sub>3</sub> TA <sub>2</sub> TGA <sub>2</sub> G
cpaBrevNT15bppwh2	GCTC <sub>2</sub> T <sub>2</sub> CG <sub>2</sub> (TCC) <sub>2</sub> TATG <sub>2</sub> ATGATC(ATG) <sub>2</sub> TA <sub>2</sub> CTC <sub>2</sub>
cpaABKodw15bppgemrev4	(CG) <sub>2</sub> A <sub>2</sub> T <sub>2</sub> CACTAGTA <sub>2</sub> GCTA <sub>2</sub> CTCATGTA <sub>2</sub> TGT <sub>2</sub> GA <sub>3</sub> TG
cpaABKodw15bpkmsacBfw3	CAGCTC <sub>2</sub> AGC <sub>2</sub> TACATAGAG <sub>2</sub> A <sub>2</sub> TA <sub>3</sub> TGAT <sub>4</sub> G <sub>2</sub> TAG <sub>3</sub>
cpaABKOup15bppgemfw2	C <sub>2</sub> G <sub>2</sub> C <sub>2</sub> GC <sub>2</sub> ATG <sub>2</sub> CGTCTACAGTAG <sub>2</sub> TG <sub>2</sub> CG <sub>2</sub> TG
CpaABkou15bpkmsacBrev1	ACG <sub>2</sub> ATC <sub>4</sub> G <sub>2</sub> A <sub>2</sub> T <sub>2</sub> A <sub>2</sub> GCAC <sub>3</sub> A <sub>2</sub> CTA(TG) <sub>2</sub> CATAGC
kpnIcpaABrevlocus	(AT) <sub>2</sub> G <sub>2</sub> TAC <sub>2</sub> AC <sub>2</sub> T(AC) <sub>2</sub> CA(CG) <sub>2</sub> T <sub>2</sub> C <sub>2</sub> TGTA <sub>3</sub> TA <sub>3</sub> TA <sub>2</sub> GC
pstIcpaABfwlocus	(AT) <sub>2</sub> CTGCAGCTA(TC) <sub>2</sub> AGC <sub>2</sub> AT <sub>3</sub> GT <sub>3</sub> CT <sub>2</sub> C <sub>2</sub> TGT <sub>2</sub> A <sub>2</sub> CTG
Pet28ahisfw	CAC <sub>2</sub> (ACC) <sub>4</sub> ACT(GA) <sub>2</sub> T
Pet28auprev	CATG <sub>2</sub> (TA) <sub>2</sub> (TC) <sub>2</sub> (CTT) <sub>2</sub> A <sub>3</sub> GT
CytocpaBrev	(GTG) <sub>5</sub> TG <sub>2</sub> ATGATC(ATG) <sub>2</sub> TA <sub>2</sub> CTC <sub>2</sub> TG
CytoCpaBfw	AG <sub>2</sub> AGA(TA) <sub>2</sub> C <sub>2</sub> AT(GCA) <sub>2</sub> A <sub>2</sub> GT <sub>2</sub> CT <sub>2</sub> CTGCT <sub>3</sub> A <sub>2</sub> CG

**Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in *Acinetobacter* species**

Rachel L. Kinsella, Juvenal Lopez, Lauren D. Palmer, Nichole D. Salinas, Eric P. Skaar, Niraj H. Tolia and Mario F. Feldman

*J. Biol. Chem.* 2017, 292:19628-19638.

doi: 10.1074/jbc.M117.808394 originally published online October 5, 2017

---

Access the most updated version of this article at doi: [10.1074/jbc.M117.808394](https://doi.org/10.1074/jbc.M117.808394)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2017/10/05/M117.808394.DC1>

This article cites 47 references, 13 of which can be accessed free at <http://www.jbc.org/content/292/48/19628.full.html#ref-list-1>